Perioperative denosumab and systemic bone preservation in elderly patients undergoing primary total knee arthroplasty: A 2-year randomized controlled trial

Elderly TKA patients commonly suffer osteoporosis-related postoperative bone loss. High-quality 2-year RCT data on perioperative denosumab remains limited. To evaluate the 2-year effects of adjunct denosumab on systemic bone density expressed as DXA-derived T-scores, bone turnover biomarkers and postoperative functional outcomes in older adults with osteopenia or osteoporosis undergoing primary TKA. This single-center, prospective, open-label randomized controlled trial enrolled patients aged ≥ 60 years undergoing primary TKA between March 2024 and September 2024. The primary endpoints were changes in lumbar spine and femoral neck T-scores from baseline to 24 months, tested using a fixed-sequence procedure. Secondary outcomes included bone turnover markers, parathyroid hormone (PTH), 25-hydroxyvitamin D, serum calcium and phosphorus, Knee Society Scores (KSS), knee range of motion (ROM), and adverse events. The primary analysis included participants who received the allocated intervention and had post-baseline data. Of 104 randomized participants, 94 received the allocated intervention and completed 24-month follow-up; 10 withdrew before treatment initiation and had no post-baseline data. Compared with controls, participants receiving denosumab had higher lumbar spine T-scores at 12 months ( P = 0.034) and 24 months ( P = 0.014), as well as a higher femoral neck T-score at 24 months ( P = 0.048). From baseline to 24 months, between-group differences in T-score change favored denosumab for the lumbar spine (0.37, 95% CI 0.13–0.61; P = 0.003) and femoral neck (0.27, 95% CI 0.01–0.53; P = 0.040). Denosumab was associated with lower β-CTX concentrations at 6, 12, and 24 months and lower PTH concentrations at 12 and 24 months ( P < 0.05). Exploratory analyses showed greater lumbar spine T-score benefits in participants with osteoporosis, age ≥ 70 years, or KL grade 4 osteoarthritis. KSS clinical and function scores and knee ROM were also higher in the denosumab group at selected follow-up points, although these functional findings were exploratory. Adverse-event rates were similar between groups, and no severe adverse events were observed during follow-up. In this randomized trial of older adults with low bone mass undergoing primary TKA, adjunctive denosumab was associated with more favorable lumbar spine and femoral neck T-score changes and sustained suppression of bone resorption over 24 months. Functional differences were exploratory, and the clinical significance of the observed skeletal and functional effects requires confirmation in larger, blinded trials with longer follow-up.

Authors

Institutions

Publication Details

Journal
Aging Clinical and Experimental Research
Published
2026-11-18
DOI
https://doi.org/10.1007/s40520-026-03565-3
Primary Topic
Bone health and osteoporosis research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Perioperative denosumab and systemic bone preservation in elderly patients undergoing primary total knee arthroplasty: A 2-year randomized controlled trial

Jingxin Pan, Xi Wang, Gao Ying, Zhao Zhang et al.
2 links
Aging Clinical and Experimental Research
Bone health and osteoporosis research
article

Perioperative denosumab and systemic bone preservation in elderly patients undergoing primary total knee arthroplasty: A 2-year randomized controlled trial

Jingxin Pan, Xi Wang, Gao Ying, Zhao Zhang, Jianbing Ma, Zhiyang Wang, Pan Li
article en

Abstract

Elderly TKA patients commonly suffer osteoporosis-related postoperative bone loss. High-quality 2-year RCT data on perioperative denosumab remains limited. To evaluate the 2-year effects of adjunct denosumab on systemic bone density expressed as DXA-derived T-scores, bone turnover biomarkers and postoperative functional outcomes in older adults with osteopenia or osteoporosis undergoing primary TKA. This single-center, prospective, open-label randomized controlled trial enrolled patients aged ≥ 60 years undergoing primary TKA between March 2024 and September 2024. The primary endpoints were changes in lumbar spine and femoral neck T-scores from baseline to 24 months, tested using a fixed-sequence procedure. Secondary outcomes included bone turnover markers, parathyroid hormone (PTH), 25-hydroxyvitamin D, serum calcium and phosphorus, Knee Society Scores (KSS), knee range of motion (ROM), and adverse events. The primary analysis included participants who received the allocated intervention and had post-baseline data. Of 104 randomized participants, 94 received the allocated intervention and completed 24-month follow-up; 10 withdrew before treatment initiation and had no post-baseline data. Compared with controls, participants receiving denosumab had higher lumbar spine T-scores at 12 months ( P = 0.034) and 24 months ( P = 0.014), as well as a higher femoral neck T-score at 24 months ( P = 0.048). From baseline to 24 months, between-group differences in T-score change favored denosumab for the lumbar spine (0.37, 95% CI 0.13–0.61; P = 0.003) and femoral neck (0.27, 95% CI 0.01–0.53; P = 0.040). Denosumab was associated with lower β-CTX concentrations at 6, 12, and 24 months and lower PTH concentrations at 12 and 24 months ( P < 0.05). Exploratory analyses showed greater lumbar spine T-score benefits in participants with osteoporosis, age ≥ 70 years, or KL grade 4 osteoarthritis. KSS clinical and function scores and knee ROM were also higher in the denosumab group at selected follow-up points, although these functional findings were exploratory. Adverse-event rates were similar between groups, and no severe adverse events were observed during follow-up. In this randomized trial of older adults with low bone mass undergoing primary TKA, adjunctive denosumab was associated with more favorable lumbar spine and femoral neck T-score changes and sustained suppression of bone resorption over 24 months. Functional differences were exploratory, and the clinical significance of the observed skeletal and functional effects requires confirmation in larger, blinded trials with longer follow-up.

Aging Clinical and Experimental Research
Shanxi Medical University (CN), Shaanxi Provincial People's Hospital (CN), Xi'an Honghui Hospital (CN), Xijing Hospital (CN), Shanxi Provincial People’s Hospital (CN), Xi'an Jiaotong University (CN), Air Force Medical University (CN)
Good health and well-being
Bone health and osteoporosis research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon